Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAST-AB trial of local triple-antibiotic prophylaxis in implant-based breast reconstruction
2024-517672-38-00Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Sep 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gentamicin, vancomycin and cefazolin in surgical site infection (SSI) and breast implant infection (2 arms), sponsored by Rigshospitalet. Primary endpoint: All-cause explantation of the breast implant within 180 days after breast reconstruction surgery. Started Sep 2024; status: completed.
02
Drugs
gentamicinvancomycincefazolin
03
Conditions
surgical site infection (SSI)breast implant infection
Beyond the preview
Go deeper on 2024-517672-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517672-38-00.